Shares of Novavax jumped after the biotech company said its new COVID vaccine generated a broad immune response against the now-dominant Eris variant and another fast-spreading strain of the virus.
The pharmaceutical giant has developed a cloud solution for continuously ingesting, visualizing, and transforming digital biomarker data into meaningful medical insights.